Drugs / PD1-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03944980 | Jun 2019 → Jun 2021 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03950154 | Jun 2019 → Aug 2023 | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03944980 ↗ |
| Modality | Cell therapy | “PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte (PD1-T)” NCT03944980 ↗ |
| Route | Intravenous | “PD1-T cells, 1x10\^10 (10 billion ), intravenous infusion,d14” NCT03944980 ↗ |